Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

Figure 1

Legend Kaplan-Meier survival estimate: (a) overall population, progression-free survival; (b) overall population, overall survival; (c) overall population KRAS wild-type versus KRAS mutant, progression-free survival; (d) overall population KRAS wild-type versus KRAS mutant, overall survival; (e) liver-limited versus other/multiple metastatic sites, progression-free survival; (f) liver-limited versus other/multiple metastatic sites, overall survival.

(a) 11 months (3–78+)

(b) 21 months (6–78+)

(c)

(d)

(e)

(f)